MRK Stock - Merck & Co., Inc.

The recent deceleration of Gardasil sales in China represents a significant structural shift for Merck & Co. (MRK), as the region has historically accounted for approximately 60% to 70% of the vaccine's international revenue. Following the Q4 2024 earnings cycle and subsequent updates in early 2025, Merck has implemented a "rebasing" strategy to address elevated inventory levels and intensifying local competition.

2025 Volume Guidance and Shipment Adjustments

Merck has significantly revised its 2025 outlook for Gardasil in China to account for a massive inventory overhang at its local distribution partner, Chongqing Zhifei Biological Products.

• Shipment Pause: Merck announced a temporary halt of Gardasil shipments to China beginning in February 2025, which is expected to last through at least the end of the year. This move is designed to allow the channel to digest excess inventory, which reached 21.9 billion yuan as of Q1 2025.
• Revenue Guidance: For the full year 2025, Merck’s guidance for Gardasil in China assumes zero shipments at the low end and less than $1 billion at the high end. This is a precipitous decline from the $3.5 billion in sales recorded in 2024.
• Volume Impact: Actual sales in China plummeted to $193 million in 2025, representing a -94% year-over-year contraction in that specific market.

Local Competitive Dynamics

The long-term growth trajectory of the Gardasil franchise is being challenged by the emergence of domestic Chinese alternatives that offer comparable efficacy at significantly lower price points.

• Wantai’s 9-Valent Launch: In June 2025, China approved its first domestically developed 9-valent HPV vaccine, Cecolin 9 (Wantai Bio-Pharm). This product directly competes with Gardasil 9 and is priced at approximately 499 yuan (~$70) per dose—a 60% discount compared to Gardasil 9’s price of roughly 1,300 yuan.
• Pricing Pressure: Local competitors like Walvax and Beijing Health Guard are also advancing 9-valent candidates. The "Class II" (out-of-pocket) vaccine market in China is highly sensitive to discretionary spending, which has weakened due to broader macroeconomic headwinds.
• Government Procurement: Several provincial governments have initiated pilot programs to provide free or subsidized domestic HPV vaccines. As domestic 9-valent options scale, they are likely to be prioritized for national immunization programs, potentially relegating Gardasil to a niche, premium segment.

Long-Term Growth Trajectory and Risks

The combination of inventory issues and local competition has led Merck to fundamentally reassess the franchise's peak potential.

• Target Withdrawal: Merck has officially withdrawn its long-term annual sales target of $11 billion by 2030. Management cited the "uncertain timing of an economic recovery in China" and the need to "remove the dialogue" around this target until market dynamics stabilize.
• Market Share Erosion: While Merck recently received approval for Gardasil in the male population (ages 9–26) in China, local rivals are already conducting Phase 3 trials for the same indication, suggesting Merck's first-mover advantage in this segment may be short-lived.
• Global Offsets: Outside of China, the franchise remains robust, with double-digit growth in regions like Japan and the U.S. However, the global transition toward single-dose recommendations by organizations like the WHO and CDC (which recently reduced recommended doses for children) poses an additional long-term volume headwind for the franchise.

The latest clinical development milestones for Merck’s subcutaneous (SC) formulation of Keytruda (pembrolizumab), recently approved as Keytruda Qlex, represent a cornerstone of the company’s "lifecycle management" strategy. By successfully transitioning the delivery mechanism from a 30-minute intravenous (IV) infusion to a 1-to-2-minute injection, Merck is positioning itself to mitigate the dual threats of the 2028 patent cliff and the Inflation Reduction Act (IRA) price negotiations.

🧬 Clinical Milestones & Regulatory Status

The clinical program for subcutaneous pembrolizumab has reached critical maturity, providing the evidentiary basis for Merck’s market defense:

• FDA & EC Approvals: In September 2025, the FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for all adult solid tumor indications previously held by the IV version. The European Commission followed with approval in November 2025.
• Phase 3 Success (MK-3475A-D77): The pivotal trial met its primary pharmacokinetic (PK) endpoints, demonstrating non-inferiority in drug exposure (AUC) and trough concentration (Ctrough) compared to the IV formulation.
• Operational Efficiency: Data showed a 47.4% reduction in patient treatment room time and a 45.7% reduction in healthcare provider active time, creating a strong value proposition for clinics and hospitals.

🛡️ Strategic Defense Against the 2028 Patent Cliff

Merck’s primary objective is to convert 30% to 40% of the existing Keytruda IV patient base to the SC formulation within 12 to 18 months of launch. This "product hopping" strategy serves several defensive purposes:

• Intellectual Property Extension: While the core compound patent for pembrolizumab expires in December 2028, the SC formulation is protected by a new patent estate—including the co-formulation with Alteogen’s hyaluronidase—that could extend exclusivity into the mid-2030s.
• Market Share Retention: By shifting patients to a more convenient SC version before biosimilars enter the market in 2028/2029, Merck can "lock in" market share. Biosimilar manufacturers will initially only be able to replicate the IV version, leaving the SC market as a proprietary stronghold for Merck.
• Patent Bridge: Merck is also defending method-of-making and method-of-use patents that may push the IV patent cliff to May or November 2029, providing a longer window for the SC transition.

⚖️ Impact on IRA Price Negotiations

The SC formulation provides a potential regulatory "safe harbor" or at least a separate pricing track under current CMS (Centers for Medicare & Medicaid Services) guidance:

• Fixed-Combination Distinction: Under the IRA, CMS typically aggregates all dosage forms of a single "active moiety." However, CMS guidance specifies that a fixed-combination drug (like Keytruda Qlex, which combines pembrolizumab with an enzyme) is treated as a separate single-source drug.
• Negotiation Delay: Keytruda IV is expected to be selected for IRA price negotiations as early as 2026, with Maximum Fair Prices (MFP) taking effect in 2028. Because Keytruda Qlex is a new BLA (Biologics License Application), its own 13-year clock for biologic negotiation eligibility could potentially reset, or at least operate independently of the IV version's price cuts.
• Pricing Flexibility: Merck has indicated it will price the SC version "at parity" with the IV version initially but may use aggressive volume-based pricing to compete with biosimilars and government-negotiated prices later in the decade.

⚠️ Risks and Uncertainties

Despite these milestones, Merck faces significant hurdles:

• Legal Challenges: Halozyme Therapeutics has alleged that Merck’s SC formulation infringes on its hyaluronidase patents. A loss in this litigation could result in royalty obligations or injunctions.
• Adoption Barriers: While SC is more convenient, many oncology centers are financially incentivized by the "buy-and-bill" model of IV infusions. Merck must ensure that the reimbursement codes (J-codes) for Keytruda Qlex remain attractive to providers.
• Regulatory Scrutiny: Federal regulators and organizations like I-MAK have criticized the SC transition as a "patent thicket" strategy, which could lead to future legislative or CMS policy changes aimed at closing the "fixed-combination" loophole.

The commercial launch of Winrevair (sotatercept) has established a high-growth foundation for Merck’s cardiovascular (CV) franchise, serving as a primary pillar in the company’s strategy to mitigate the projected revenue erosion from the Keytruda patent cliff. Current adoption metrics and payer dynamics suggest that while the CV portfolio is scaling rapidly, its ability to fully offset oncology gaps within a strict three-year window depends on the successful Phase 3 readout and launch of follow-on assets like MK-0616.

📈 Winrevair Commercial Trajectory & Physician Adoption

Winrevair’s launch is widely regarded by analysts as one of the most successful in the rare disease space, driven by its "disease-modifying" clinical profile rather than mere symptom management.

• Sales Performance: In its first full year of availability (2025), Winrevair generated $1.4B in global sales, a significant jump from the $419M recorded during its partial launch year in 2024.
• Physician Sentiment: Surveys of cardiologists and pulmonologists indicate that approximately 10% of the U.S. PAH patient population was transitioned to Winrevair by early 2025. Adoption is accelerating due to "real-world" safety data showing lower-than-expected bleeding risks compared to the pivotal STELLAR trial.
• Clinical Catalysts: The ZENITH and HYPERION trials have provided clinical evidence for "upstream" use in recently diagnosed and high-risk patients. This is expected to expand the addressable market from late-stage rescue therapy to a first-line foundational treatment.

⚖️ Payer Coverage & Market Access

Payer coverage has stabilized following initial "early access" hurdles, with broad formulary placement across Medicare and major commercial insurers.

• Medicare Integration: As of 2025, the Medicare Prescription Payment Plan and the $2,000 out-of-pocket cap for Part D have significantly reduced the financial barrier for elderly PAH patients, who represent a substantial portion of the market.
• Prior Authorization (PA): Coverage remains subject to strict PA criteria. Most major payers (e.g., UnitedHealthcare, Cigna) require a PAH diagnosis confirmed by right heart catheterization and documentation that the patient is symptomatic despite background therapy.
• Reimbursement Efficiency: Merck’s "Access Program" has successfully navigated these PA hurdles, with the company reporting that the time-to-therapy for new patients has normalized to industry standards for specialty biologics.

🛡️ Portfolio Scaling vs. Oncology Revenue Gap

Merck faces a concentrated loss-of-exclusivity (LOE) event for Keytruda starting in late 2028. The CV portfolio is the tip of the spear in a "diversification wall" intended to replace this revenue.

• The Oncology Gap: Keytruda sales reached $31.7B in 2025. Analysts project a revenue hit of approximately -$27.4B post-LOE. Merck’s strategy involves migrating 30-40% of patients to the subcutaneous Keytruda Qlex by 2028 to retain market share.
• Cardiovascular Contribution: Merck has set a target of $10B+ in annual CV revenue by the mid-2030s.
  • Winrevair: Projected peak sales of $3B - $5B.
  • MK-0616 (Oral PCSK9): This "blockbuster-in-waiting" for high cholesterol is in Phase 3, with primary completion expected in late 2025. If launched by 2026/2027, it could contribute billions in the 2028-2030 window.
• Portfolio Breadth: Beyond Winrevair, Merck is advancing eight new CV launches by 2030, including an Lp(a) inhibitor and MK-2060 (anticoagulant).

⚠️ Risks & Strategic Limitations

Despite the strong start, several factors could impede Merck’s ability to fully bridge the oncology gap:

1. IRA Price Negotiations: Keytruda and other top-tier drugs face Medicare price setting under the Inflation Reduction Act, which may compress margins before the actual patent expiry.
2. Execution Risk in PCSK9: The oral PCSK9 market is highly competitive. While Merck’s MK-0616 is a first-in-class oral pill, it must compete with established, long-acting injectables like Repatha and Leqvio.
3. Scaling Velocity: Even with Winrevair’s 141% YoY growth, the absolute dollar contribution from the CV segment currently remains a fraction of the oncology franchise. The "next three years" (2026-2028) will be a period of heavy R&D and SG&A investment, likely pressuring margins until the new portfolio reaches critical mass.